Founders & CXOs
Graviti Pharmaceuticals Has Entered Karnataka — A Hyderabad USFDA-Compliant Pharma Company Just Landed in Bengaluru's Market
By Mustafa Shariff, Editor in Chief · April 27 , 2026 · 5 min read
Summary
- Graviti Pharmaceuticals Enters Karnataka: What the Hyderabad Pharma Company's Bengaluru Expansion Signals
- Graviti Pharmaceuticals has launched Karnataka operations after establishing its India domestic business in Andhra Pradesh and Telangana. Here is the full story and what this expansion signals for Bengaluru's pharmaceutical market.
Graviti Pharmaceuticals, a Hyderabad-headquartered pharmaceutical company with a strong and growing presence in international markets — particularly the United States — has formally announced the launch of its operations in Karnataka, marking its entry into India's most innovation-intensive state healthcare market. The expansion follows the completion of one year of operations in Andhra Pradesh and Telangana, where Graviti has built its initial India domestic market presence after establishing its international business foundation.
Graviti Pharmaceuticals is not a small or early-stage company. The company recorded revenue of ₹544 crore in FY25 and employs 1,142 people — figures that reflect a substantial operating pharmaceutical business built primarily on international market strength. Its manufacturing facility at Pashamylaram, Hyderabad, operates in alignment with USFDA standards — a quality certification that positions Graviti's products at the compliance level required by the most demanding global regulatory authorities. The company has additional ongoing filings in the UK and Europe, reflecting international ambitions that extend beyond its established US position.
The Karnataka Strategic Rationale
Karnataka, and specifically Bengaluru, represents a qualitatively different market opportunity for a company like Graviti compared to Andhra Pradesh and Telangana. Karnataka's healthcare infrastructure is India's most advanced by several measures: the state's hospital bed density is among India's highest, Bengaluru's concentration of multi-specialty hospital groups (Manipal, Narayana, Apollo, Fortis, Sakra World, Aster) creates significant institutional pharma procurement volumes, and the state's network of NABH-accredited hospitals reflects clinical sophistication that favours quality-led pharmaceutical suppliers over price-only competitors.
Graviti's portfolio focus — cardiovascular and central nervous system medications, with planned expansion into gastroenterology and urology — maps well to Karnataka's disease burden and hospital purchasing patterns. Cardiovascular disease is the leading cause of mortality in Karnataka as in the rest of India. The state's ageing urban population creates sustained demand for CNS medications addressing neurological conditions, psychiatric disorders, and movement diseases. The planned gastro and urology additions further broaden Graviti's relevance to Karnataka's hospital formularies.
Thilak Vangala, Graviti's Chief Operating Officer, articulated the strategic positioning: Karnataka is a very strategic market, and Graviti's focus on high-quality standards and price competitiveness positions it to capture a meaningful share of a market that values both clinical quality credentials and competitive pricing.
The Bengaluru Pharma Market Context
Bengaluru's pharmaceutical retail and hospital market is served by companies across the quality spectrum — from multinational brands at premium prices to domestic generic players at the lowest price points. The middle segment — companies that offer USFDA-quality products at India-competitive prices — has historically been underserved relative to the demand from Bengaluru's quality-sensitive hospital procurement committees and specialist physicians who manage patients on complex multi-medication regimens.
Graviti's positioning — internationally validated quality systems at domestic market price points — is targeted at exactly this segment. The company's COO Akula Krishna Kishore noted that Graviti produces complex generics of the highest quality, especially in cardiovascular and CNS areas, and that the Karnataka expansion marks another chapter in the company's growth story.
BHC Perspective
At Bengaluru Health Community, Graviti's Karnataka entry is a story about Bengaluru's pharmaceutical market continuing to attract quality-led pharma companies from the Hyderabad cluster. The Hyderabad-Bengaluru axis — connecting India's pharma manufacturing capital with its healthcare innovation capital — is becoming an increasingly important commercial corridor. For BHC's healthcare founders and hospital partners, the entry of USFDA-compliant pharmaceutical companies into Bengaluru's market improves the quality of the medicine supply chain that their products and partnerships depend on.
Frequently Asked Questions
Q: What is Graviti Pharmaceuticals?
A: A Hyderabad-based pharmaceutical company with ₹544 crore FY25 revenue, 1,142 employees, a USFDA-compliant manufacturing facility at Pashamylaram, and international presence in the US with filings in the UK and Europe. Focus: cardiovascular and CNS medications, expanding to gastro and urology.
Q: Why has Graviti entered Karnataka?
A: Karnataka's advanced hospital infrastructure, high hospital bed density, concentration of major hospital groups, and quality-sensitive institutional pharma procurement make it a strategically valuable market for a USFDA-quality pharmaceutical company positioning on quality and price competitiveness.
Q: What is Graviti's growth trajectory?
A: After establishing operations in Andhra Pradesh and Telangana over its first year of India domestic operations, the Karnataka launch extends Graviti's South India presence as it builds toward a national India market footprint alongside its established international business.